A team of scientists at UCL have found that blood tests measuring the hallmark Alzheimer’s protein, b-amyloid (amyloid), could radically reduce the cost of clinical trials and potentially open the door to treating the disease earlier. The scientists studied a unique group of volunteers, who were all born in the same week in 1946. The findings are published on Tuesday 19 January, in the journal Brain.